Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.

Original publication

DOI

10.1186/bcr1796

Type

Journal article

Journal

Breast Cancer Res

Publication Date

2007

Volume

9

Keywords

Angiogenesis Inhibitors, Angiogenic Proteins, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bevacizumab, Biomarkers, Tumor, Breast Neoplasms, Cell Hypoxia, Female, Humans, Neovascularization, Pathologic, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A